Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Additional research on biomarkers in ‘Phase II study of panitumumab rechallenge in the third-line therapy in patients with KRAS wild-type metastatic colorectal cancer (JACCRO CC-09) "

ABSTRACT: Interventions: Collecting blood 16mL at the time of before JACCRO CC-09 protocol treatment, 8 weeks after protocol treatment, and PD. Primary outcome(s): Tumor-related gene variation analysis using plasma free DNA Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2631242 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Additional research on biomarkers in ‘Phase II study of cetuximab rechallenge in the third-line therapy in patients with KRAS wild-type metastatic colorectal cancer (JACCRO CC-08) &quot

Project description:Interventions: Collecting blood 16mL at the time of before JACCRO CC-08 protocol treatment, 8 weeks after protocol treatment, and PD. Primary outcome(s): Tumor-related gene variation analysis using plasma free DNA Study Design: Single arm Non-randomized

| 2631240 | ecrin-mdr-crc

Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08.

Project description:BackgroundRegorafenib or trifluridine/tipiracil as third-line treatment have limited efficacy in metastatic colorectal cancer (mCRC).MethodsThis Phase 2 trial evaluated the efficacy and safety of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type mCRC patients who achieved clinical benefit with first-line cetuximab-containing therapy. The primary endpoint was 3-month progression-free survival (PFS) rate. A sample size was calculated; 30 patients with a 3-month PFS rate of 45% deemed promising and 15% unacceptable. Patients with greater and less than the cut-off value of cetuximab-free intervals (CFIs) were classified into the long and short CFI groups, respectively, in subgroup analyses.ResultsAmong 34 eligible patients who received treatment at least once, 3-month PFS rate was 44.1% (95% confidence interval, 27.4-60.8%). The median PFS and overall survival (OS) were 2.4 and 8.2 months, respectively. The response and disease control rates were 2.9 and 55.9%, respectively. PFS and OS were significantly longer in the long- than in the short CFI group.ConclusionsIrinotecan plus cetuximab rechallenge as third-line treatment for KRAS wild-type mCRC was safe and had promising activity, especially in those with a long CFI, warranting further investigation in a Phase 3 randomised trial.Clinical trial registrationUMIN000010638.

| S-EPMC7652864 | biostudies-literature

CMS classification of the CC-531 cells, CC-531 organoids and CC-531 ex vivo tumor tissue grown in the peritoneum of rats

Project description:To investigate the CMS subtype of the CC-531 cells, CC-531 organoids and CC-531 ex vivo tumor tissue grown in the peritoneum of WAG/Rij rats We then performed gene expression profiling analysis using data obtained from RNA-seq of CC-531 cells, CC-531 organoids and CC-531 ex vivo tumor tissue grown in the peritoneum of WAG/Rij rats of three different passages per sample type.

2023-03-03 | GSE226558 | GEO

Project description:CC Metagenome

| PRJNA894811 | ENA

Chlamydomonas reinhardtii strain:CC-425 x CC-124 | cultivar:CC-425 x CC-124

Project description:Chlamydomonas reinhardtii CC-425 x CC-124 transcriptome

| PRJNA370690 | ENA

Identification and characterization of CC-AMP1-like and CC-AMP2-like peptides in Capsicum spp.

Project description:Antimicrobial peptides (AMPs) are compounds with a variety of bioactive properties. Especially promising are their antibacterial activities, often towards drug-resistant pathogens. Across different AMP sources, AMPs expressed within plants are relatively underexplored, with a limited number of plant AMP families identified. Recently, we identified the novel AMPs CC-AMP1 and CC-AMP2 in ghost pepper plants (Capsicum chinense x frutescens), exerting promising antibacterial activity and not classifying into any known plant AMP family. Herein, AMPs related to CC-AMP1 and CC-AMP2 were identified within both Capsicum annuum and Capsicum baccatum. Targeted MS/MS experiments were performed to determine peptide sequences, guided by in silico AMP sequence predictions.

2024-01-27 | PXD041035 | Pride

CC-122 versus Lenalidomide

Project description:Gene expression profiles of OSU-CLL cells were tested after exposure to CC-122 (0.1 and 1 micromolar), Lenalidomide (1 micromolar), or DMSO, at 5 and 24 hours

2021-06-04 | GSE115328 | GEO

Comparison among samples subjected to a novel in vitro tissue culture system, VISUAL-CC

Project description:We established a novel in vitro tissue culture system (named VISUAL-CC), in which phloem companion cell (CC) differentiation can be induced with Arabidopsis thaliana cotyledons. To compare gene expression profiles between VISUAL and VISUAL-CC, we conducted GeneChip analysis using two different in vitro cultures. CC-S means a sample that strongly induces CC differentiation. CC-M means a sample that moderately induces CC differentiation. V means a VISUAL sample, that does not induce CC differentiation at all.

2020-03-31 | GSE141037 | GEO

RNAseq Study in CC-671 Treated Cal-51 Cells

Project description:CC-671 has been identified as an inhibitor of Cdc2-like kinase 2 (CLK2) and TTK in direct enzyme assays. CLK2 is a member of the CLK family that phosphorylates serine- and arginine-rich (SR) proteins of the spliceosomal complex as part of a regulatory mechanism for control of pre-mRNA splicing. SR proteins are a family of small nuclear ribonucleoprotein particle (snRNP) splicing factors involved in constitutive and alternative splicing. Monitoring specific phospho-biomarkers of CLK2 demonstrated that CC-671 inhibited phosphorylation of CLK2 substrates in cancer cells with mean IC50 of 549 nM in the triple negative breast cancer (TNBC) line CAL51. In this study, RNA sequencing approach was used to quantify the impact of CC-671 treatment on gene transcription and global alternative splicing in CAL51 cells. Differential exon usage analysis demonstrated that CC-671 changed alternative splicing of many genes. In addition, different sets of genes are impacted by CC-671 at both the alternative splicing and mRNA expression. Genes impacted by alternative splicing shared a set of common pathways with genes altered by mRNA expression. This result indicates that CC-671 regulates transcription via both gene expression and alternative splicing mechanisms.

2018-04-23 | GSE113426 | GEO

Duke CC

Project description:Duke CIVICs Clinical Core (Duke CC)

| PRJNA1055131 | ENA